Omega-3 fatty acids and inflammatory processes: from molecules to man.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing molecular mechanisms, animal models, and clinical literature without systematic review methodology.
PubMed 28900017 · doi:10.1042/BST20160474
What was done
This narrative review describes nutritional and metabolic aspects of omega-3 and omega-6 fatty acids, explains the cellular and molecular mechanisms of EPA and DHA in inflammatory processes, and summarizes evidence from animal experiments and human clinical trials.
What was found
No quantitative data, effect sizes, or statistical metrics are reported in the abstract. Narratively, EPA and DHA are described as suppressing leukocyte chemotaxis, adhesion molecule expression, leukocyte-endothelial interactions, pro-inflammatory eicosanoid production from arachidonic acid, and pro-inflammatory cytokine production. They serve as precursors for anti-inflammatory and pro-resolving mediators (resolvins, protectins, maresins), alter membrane phospholipid fatty acid composition, disrupt lipid rafts, inhibit NF-κB activation, and activate PPAR-γ. Human trials are noted to show benefits of oral omega-3s in rheumatoid arthritis and atherosclerotic plaque stabilization, as well as intravenous formulations in critically ill patients.
Why it matters
It provides a comprehensive overview mapping the biological mechanisms through which dietary and supplemental omega-3 fatty acids regulate active inflammation and resolution pathways in human disease.
Limits
The abstract reports no numerical findings, study numbers, or sample sizes. As a narrative review rather than a systematic review or meta-analysis, it lacks formal study selection criteria, risk-of-bias grading, and quantitative effect estimates.
Cited by
- supports Omega-6 fatty acids (linoleic acid) metabolize into inflammatory molecules, whereas omega-3 fatty acids metabolize into anti-inflammatory compounds.